Clinical trial results

Explore the landscape of Clinical trial results in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Clinical trial results to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World's First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer
CompanyDrug

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World’s First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

Alphamab Oncology (HKG: 9966) announced that the first patient has been successfully dosed in the Phase III clinical study of JSKN033 monotherapy for recurrent or metastatic cervical cancer – irrespective…

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Eli Lilly's Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

Eli Lilly’s Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

ASH 2022: China Biotechs Showcase Latest Clinical Trial Results

CompanyDrug

Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022

CompanyDrug

Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study

CompanyDrug

Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia

CompanyDrug

Kintor’s KX-826 Reaches Primary Endpoint in Phase II Study for Female AGA

CompanyDrug

Simcere’s Edaravone, Borneol Sublingual Tablets Reach Phase III Efficacy Endpoint

CompanyDrug

Clover Biopharmaceuticals’ SCB-2019 Vaccine Reduces Household Transmission of COVID-19

CompanyDrug

Alphamab Oncology and CSPC Announce Positive Phase II Data for KN026 in HER2-Positive Gastric Cancer

Show More